Trust Signals
This page cites only real, published sources. Every major claim is graded by evidence type in the ledger table below. Where human data does not exist, we say so plainly. No affiliate products are embedded in this comparison. The goal is a reference a clinician or researcher would trust, not a sales funnel.
Key Takeaways
- ACE-031 is a synthetic ActRIIB-Fc fusion protein that traps multiple TGF-beta ligands simultaneously; follistatin 344 is a naturally occurring isoform that binds activins and myostatin via a wrapping mechanism involving three follistatin domains.
- ACE-031 has genuine Phase 1 and Phase 2 human trial data from Acceleron Pharma, including lean mass increases in healthy postmenopausal women; follistatin 344 has no direct human peptide-injection trial data.
- The Phase 2 Duchenne trial of ACE-031 was halted because of vascular adverse events (epistaxis, telangiectasia) tied to suppression of BMP9 and BMP10 signaling, a real safety signal that commodity pages consistently understate.
- ACE-031 has a reported serum half-life of roughly 10 to 14 days in humans due to its Fc fusion; endogenous follistatin circulates for minutes to a few hours, and injected peptide-grade follistatin 344 half-life in humans is unknown.
- Both compounds are prohibited by WADA under myostatin inhibitor and peptide hormone categories, and research-vendor quality is highly unreliable for proteins of this structural complexity.
What Is ACE-031 vs Follistatin 344? (Direct Answer)
Table of Contents
- What are ACE-031 and follistatin 344 structurally?
- How do their mechanisms differ at the molecular level?
- What does the evidence actually show? (Evidence Ledger)
- What most comparison pages get wrong
- The vascular safety signal: why ACE-031 trials were stopped
- Half-life, dosing, and pharmacokinetics
- Honest head-to-head table
- Sourcing, quality, and COA literacy for large proteins
- Regulatory and anti-doping status
- FAQ
- Sources
What Are ACE-031 and Follistatin 344 Structurally?
ACE-031 (also written ACE031) is a recombinant fusion protein created by joining the extracellular domain of activin receptor type IIB (ActRIIB) to the Fc region of human IgG1. The resulting molecule weighs roughly 120 kDa. Because it presents the ActRIIB binding surface without an intracellular signaling domain, it acts as a decoy receptor, capturing ligands before they can engage cell-surface receptors. Acceleron Pharma developed it specifically to be a broader and longer-lasting inhibitor than a simple myostatin antibody.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Follistatin 344 is one of two primary splice isoforms of the human follistatin gene (FST). The number 344 refers to the amino acid count of the mature protein after signal peptide cleavage. The 344 isoform differs from the 288 isoform primarily at its C-terminal tail: the 344 form has an acidic extension that reduces affinity for heparan sulfate proteoglycans on cell surfaces, causing it to circulate more freely in plasma. Both isoforms contain three tandem follistatin domains (FS1, FS2, FS3) that physically wrap around and neutralize target ligands. The protein is glycosylated in native form, a detail that is critical for sourcing discussions below.
How Do Their Mechanisms Differ at the Molecular Level?
Both compounds ultimately reduce signaling through the SMAD2/3 pathway (activin-like signals) and, to varying degrees, the SMAD1/5/8 pathway (BMP signals). The breadth of that suppression is where they diverge significantly.
ACE-031 binds any ligand that uses ActRIIB as its primary signaling receptor. That list is long: myostatin (GDF-8), activin A, activin B, GDF-11, BMP9, and BMP10, among others. BMP9 and BMP10 are the ligands responsible for the vascular adverse events seen in trials (explained further below). The broad capture is intentional for maximal muscle effect but creates collateral suppression of non-muscle pathways.
Follistatin 344 binds through a physically distinct wrapping mechanism. Its three follistatin domains encircle the target ligand, blocking receptor access. Its preferred targets are activin A, activin B, and myostatin. It binds BMPs with lower affinity relative to activins. This selectivity profile is somewhat narrower than ACE-031's, which may translate to a different safety margin, though this has not been tested head-to-head in humans.
A key mechanistic caveat: both compounds suppress pathways that do far more than control muscle size. Activins regulate reproductive biology, red blood cell production (via erythroid progenitors), bone remodeling, and immune function. Suppressing them broadly has systemic consequences that muscle-focused framing consistently underplays.
What Does the Evidence Actually Show? (Evidence Ledger)
| Claim | Best Evidence Type | Direction | Confidence | Key Caveat |
|---|---|---|---|---|
| ACE-031 increases lean mass in humans | Phase 1 human RCT (Acceleron, healthy postmenopausal women, n=48) | Positive, statistically significant lean mass increase reported | Moderate | Single trial, not in healthy young adults, trial halted before Phase 3 |
| ACE-031 causes vascular adverse events | Phase 2 human trial (Duchenne, Acceleron), trial stopped | Negative, real safety signal | High | Frequency and severity in healthy adults vs. diseased children unknown |
| Follistatin 344 increases muscle mass (animal) | Multiple rodent studies, some non-human primate data | Positive, robust in animals | Moderate (animal only) | Animal to human translation for this pathway has failed before |
| Follistatin increases muscle in humans (gene therapy) | Small open-label human gene therapy trial (Mendell et al., Molecular Therapy 2015, n=6) | Modest positive functional signal | Low (open label, very small, gene therapy not peptide injection) | AAV vector delivery is not comparable to injected peptide |
| Follistatin 344 injected peptide increases muscle in humans | No human trial data | Unknown | Very Low (extrapolation from animal and gene therapy) | No human pharmacokinetic or efficacy data for injected protein exists |
| ACE-031 half-life ~10 to 14 days in humans | Acceleron Phase 1 PK data (published in summary form) | Established range | Moderate | Full PK dataset not published in peer-reviewed journal in detail |
| Both compounds inhibit myostatin signaling | In vitro receptor-binding studies, animal models | Positive, well established mechanistically | High (mechanism) / Low (clinical relevance in healthy humans) | Mechanism established; whether that translates to meaningful human outcomes in healthy individuals is unproven |
What Most Comparison Pages Get Wrong
The broadest omission: Almost every bodybuilding or research-compound page treats ACE-031 and follistatin 344 as interchangeable "myostatin blockers" with a simple potency ranking. This misses three critical realities:
- ACE-031 is not a peptide. It is a roughly 120 kDa recombinant fusion protein, structurally more similar to a biologic therapeutic like etanercept than to a research peptide like BPC-157. Calling it a "peptide" in the same breath as follistatin 344 obscures meaningful differences in manufacturing requirements, immunogenicity risk, and stability.
- The ligand breadth matters enormously. Blocking BMP9 and BMP10 suppresses the ALK1 pathway in vascular endothelium. This is not a theoretical risk; it is the documented mechanism behind telangiectasia seen in Acceleron's Duchenne trial. Pages that mention the trial pause without explaining this mechanism leave readers unable to evaluate their own risk.
- Research-vendor follistatin 344 is almost certainly not biologically equivalent to human follistatin. Native follistatin is glycosylated, and glycosylation affects ligand-binding affinity, half-life, and immunogenicity. Vendors producing follistatin 344 via E. coli expression systems yield a non-glycosylated product whose in vivo behavior is genuinely unknown. This is a critical formulation gotcha covered in the sourcing section.
The Vascular Safety Signal: Why the ACE-031 Trial Was Stopped
In 2011 and 2012, Acceleron halted enrollment in its Phase 2 Duchenne muscular dystrophy trial after a subset of patients developed epistaxis (nosebleeds) and telangiectasia (small vascular dilations visible on skin). These events pointed to disruption of endothelial homeostasis.
The mechanistic explanation traces to BMP9 and BMP10, which are high-affinity ActRIIB ligands and the primary activators of ALK1 (activin receptor-like kinase 1) signaling in vascular endothelium. ALK1 signaling maintains endothelial quiescence and is essential for vascular stability. Loss-of-function mutations in ALK1 or its coreceptor endoglin cause hereditary hemorrhagic telangiectasia in humans, a naturally occurring disease with symptoms strikingly similar to those seen in the ACE-031 trial. ACE-031, by capturing BMP9 and BMP10 as collateral targets alongside myostatin, effectively mimics partial ALK1 pathway deficiency.
This risk may not apply identically to follistatin 344, which binds BMP9 and BMP10 with lower affinity than ACE-031. However, it has not been tested. The honest position is that any intervention broadly suppressing ActRIIB ligands carries a plausible vascular risk that has not been ruled out for follistatin 344 in humans.
Half-Life, Dosing, and Pharmacokinetics
ACE-031's Fc fusion design grants it a half-life of approximately 10 to 14 days in humans, derived from Acceleron's Phase 1 pharmacokinetic work. This is functionally important: a single subcutaneous injection produces sustained ligand suppression for weeks, which limits the ability to rapidly reverse an adverse effect. The long half-life that makes it dosing-convenient is also what makes a vascular adverse event harder to manage acutely.
For follistatin 344, endogenous follistatin circulates with a plasma half-life measured in minutes to a few hours depending on context. The 344 isoform, because it binds heparan sulfate less avidly than the 288 isoform, has a somewhat longer circulating half-life than the 288 form, but this is still short. For injected recombinant follistatin 344, no reliable human pharmacokinetic data from peptide injection studies exists. Researchers who extrapolate from endogenous half-life are making a structural assumption, not citing data.
Doses used in Acceleron's Phase 1 work in postmenopausal women ranged from 0.1 mg/kg to 3 mg/kg given subcutaneously. No equivalent dose-ranging data exists for follistatin 344 as an injected compound in humans.
Honest Head-to-Head Table
| Parameter | ACE-031 | Follistatin 344 |
|---|---|---|
| Molecular class | Recombinant fusion protein (~120 kDa), Fc-fusion biologic | Glycoprotein (~35 kDa native), endogenous isoform |
| Primary ligands targeted | Myostatin, activin A/B, GDF-11, BMP9, BMP10, others | Activin A/B, myostatin; BMPs at lower affinity |
| Human efficacy data | Yes, Phase 1 and Phase 2 trial data (lean mass increase demonstrated) | No injected peptide human data; one small gene therapy trial (Mendell 2015) |
| Human safety data | Yes, includes documented vascular adverse events, trial halted | No systemic injection safety data in humans |
| Half-life (human) | Approximately 10 to 14 days (Fc-mediated FcRn recycling) | Unknown for injected form; endogenous form minutes to hours |
| Glycosylation required? | Yes, Fc-fusion requires mammalian cell expression | Yes for full biological activity; most vendor products are non-glycosylated |
| Regulatory status | Discontinued drug candidate, not approved anywhere | No approved drug form, research compound only |
| WADA status | Prohibited (myostatin inhibitor, peptide hormone class) | Prohibited (same categories) |
| Where ACE-031 wins | Actual human PK and efficacy data; known half-life; documented lean mass effect | N/A |
| Where follistatin 344 wins | N/A | Narrower ligand profile may carry lower vascular risk; endogenous biology better understood |
| Where both lose vs. alternatives | Testosterone and anabolic steroids have decades of human safety data; approved drugs for muscle wasting (oxandrolone, anamorelin in Japan) exist. Neither ACE-031 nor follistatin 344 has a risk-benefit profile established for healthy individuals. | |
Sourcing, Quality, and COA Literacy for Large Proteins
This section is what most pages omit entirely. Both ACE-031 and follistatin 344 are large, structurally complex proteins, not simple peptides. The quality gap between pharmaceutical-grade biologics and research-vendor products is enormous for compounds of this class.
ACE-031: As an Fc-fusion biologic, it requires Chinese Hamster Ovary (CHO) cell or equivalent mammalian expression to achieve correct folding, disulfide bonding, and glycosylation. No research vendor has the manufacturing infrastructure to produce ACE-031 equivalently to Acceleron's GMP process. What is sold as "ACE-031" in research markets is likely a truncated or misfolded analog of unknown potency and immunogenicity.
Follistatin 344: The native protein is N-glycosylated at multiple sites. Glycosylation affects follistatin's affinity for its ligands, its plasma half-life, and crucially its immunogenicity. Many research vendors produce follistatin 344 in E. coli, yielding a non-glycosylated product. An E. coli-expressed follistatin 344 may still bind ligands in a cell-based assay, but its pharmacokinetics and immune profile in vivo are genuinely different from the native protein. No published data exists to quantify exactly how different.
What a meaningful COA should include for these compounds:
- Molecular weight confirmed by mass spectrometry (not just stated)
- Purity by HPLC, ideally above 95% with the chromatogram visible
- Endotoxin testing (LAL assay result, with a value, not just "passed")
- Sterility or bioburden testing
- A cell-based bioactivity assay: for follistatin 344 this would be demonstrated inhibition of activin-induced SMAD2 phosphorylation; for ACE-031 it would be confirmed ActRIIB ligand capture. Sequence confirmation or mass accuracy alone does not confirm that a protein of this complexity is biologically functional.
Stability gotcha: Both compounds are proteins susceptible to aggregation, deamidation, and oxidation. ACE-031, like most Fc-fusion biologics, requires cold chain storage and is not stable at room temperature for extended periods. Follistatin 344 in lyophilized form should be stored at or below negative 20 degrees Celsius and, once reconstituted, used promptly. A cloudy, particulate, or visually degraded solution of either compound should not be used; aggregated protein carries elevated immunogenicity risk.
Regulatory and Anti-Doping Status
ACE-031 is not approved by the FDA, EMA, or any major regulatory agency. Acceleron's development program was discontinued after the trial pause, and the compound was not advanced further. The acquisition of Acceleron by Bristol Myers Squibb focused on luspatercept (a related ActRIIB-Fc fusion for anemia), not ACE-031.
Follistatin 344 has no approved pharmaceutical form anywhere in the world.
Both compounds are prohibited by WADA. The current WADA Prohibited List includes myostatin inhibitors explicitly, and both fall under the broader categories of peptide hormones, growth factors, and related substances. The prohibition applies both in-competition and out-of-competition. Athletes subject to anti-doping testing face sanctions for use of either compound regardless of approved status.
FAQ
What is the core difference between ACE-031 and follistatin 344?
ACE-031 is a fusion protein that acts as a soluble decoy receptor for multiple TGF-beta ligands including myostatin, activin A, and GDF-11. Follistatin 344 is a naturally occurring glycoprotein that also binds and neutralizes myostatin and activins but through a different structural mechanism. ACE-031 has the broader ligand-trapping profile; follistatin 344 has more established endogenous biology.
Has ACE-031 been tested in humans?
Yes. Acceleron Pharma conducted Phase 2 trials in Duchenne muscular dystrophy patients and a Phase 1 trial in healthy postmenopausal women. The Duchenne trial was halted early due to safety signals including epistaxis and telangiectasia, attributed to broad suppression of BMP and activin signaling beyond muscle tissue.
Has follistatin 344 been tested in humans?
Human data on injected or peptide-grade follistatin 344 is very limited. One small intramuscular gene therapy study (Mendell et al., 2015, Molecular Therapy) delivered follistatin via AAV vector in Becker muscular dystrophy patients and showed modest functional signals, but that is a gene therapy context, not direct peptide injection.
Which compound is stronger for muscle growth?
In animal models, both show meaningful lean mass increases. ACE-031 produced statistically significant lean mass gains in Phase 1 human data. Follistatin 344 animal data is compelling but direct human peptide-injection trials do not exist. Claiming either is proven for muscle growth in healthy humans is unsupported by current evidence.
Why was the ACE-031 Duchenne trial stopped?
The trial was paused due to adverse events including nosebleeds and small vascular lesions (telangiectasia) in a subset of patients. These were attributed to off-target suppression of BMP9 and BMP10 signaling, which regulate vascular endothelial homeostasis. The broad ligand-trapping activity of ACE-031 affects pathways beyond skeletal muscle.
What does follistatin 344 actually bind?
Follistatin 344 binds activins (especially activin A and B), myostatin (GDF-8), GDF-11, and BMPs to varying degrees. The 344 isoform circulates more freely than the 288 isoform because it binds heparan sulfate proteoglycans less tightly, giving it a broader systemic reach but a less tissue-targeted effect.
Are research-grade ACE-031 and follistatin 344 peptides reliable?
Quality is highly variable. ACE-031 is a large fusion protein (roughly 120 kDa) that is extremely difficult to manufacture correctly outside a pharmaceutical setting. Follistatin 344 is also a large glycoprotein. Most research-vendor products are not glycosylated correctly, may lack proper folding, and certificates of analysis rarely confirm biological activity. Mass accuracy alone does not confirm function.
What is the half-life of ACE-031 vs follistatin 344?
ACE-031 has a reported serum half-life of approximately 10 to 14 days in humans based on Acceleron Phase 1 pharmacokinetic data, due to its Fc fusion design. Follistatin 344 half-life in humans is not well established from injection studies; endogenous follistatin has a plasma half-life measured in minutes to a few hours in circulation.
Is ACE-031 or follistatin 344 approved by any regulatory agency?
Neither compound is approved by the FDA or any major regulatory agency for any indication. ACE-031 development was discontinued by Acceleron (now part of Bristol Myers Squibb). Follistatin 344 has no approved drug form. Both are research compounds only.
Are these compounds banned in sport?
Yes. WADA prohibits all myostatin inhibitors, peptide hormones, and their releasing factors under the Prohibited List. ACE-031 falls under myostatin inhibitors and TGF-beta pathway modulators. Follistatin and its analogs are covered under the same prohibition. Both are banned in competition and out of competition.
How do ACE-031 and follistatin 344 compare to approved alternatives for muscle wasting?
Approved options for muscle wasting include testosterone, oxandrolone (in specific indications), and anamorelin (approved in Japan for cancer cachexia). None share the exact mechanism, but testosterone and approved anabolic agents have far more human safety and efficacy data than either ACE-031 or follistatin 344 in non-disease healthy populations.
What should I look for on a certificate of analysis for these compounds?
A COA should include molecular weight confirmation by mass spectrometry, purity by HPLC (ideally above 95%), endotoxin testing (LAL assay with a numeric result), sterility testing, and ideally a cell-based bioactivity assay confirming receptor binding or signaling inhibition. Sequence confirmation alone is insufficient for proteins of this complexity.
Sources
- Attie KM, Borgstein NG, Yang Y, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle and Nerve. 2013;47(3):416-423.
- Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Molecular Therapy. 2015;23(1):192-201.
- Ueno N, Ling N, Ying SY, Esch F, Shimasaki S, Guillemin R. Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proceedings of the National Academy of Sciences. 1987;84(23):8282-8286.
- Harrison CA, Al-Musawi SL, Walton KL. Prodomains regulate the synthesis, extracellular localisation and activity of TGF-beta superfamily ligands. Growth Factors. 2011;29(5):174-186.
- Larsson L, Degens H, Li M, et al. Sarcopenia: Aging-Related Loss of Muscle Mass and Function. Physiological Reviews. 2019;99(1):427-511. (Background on myostatin pathway in muscle biology.)
- Oh SP, Seki T, Goss KA, et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proceedings of the National Academy of Sciences. 2000;97(6):2626-2631. (ALK1 and vascular biology context.)
- WADA Prohibited List 2024. World Anti-Doping Agency. Available at: wada-ama.org/en/prohibited-list. (Myostatin inhibitor and peptide hormone categories.)
- Shimasaki S, Koga M, Esch F, et al. Primary structure of the human follistatin precursor and its genomic organization. Proceedings of the National Academy of Sciences. 1988;85(12):4218-4222.
- Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Developmental Cell. 2005;9(4):535-543.
- Acceleron Pharma. ACE-031 program summary and clinical trial history. Publicly disclosed via SEC filings and conference presentations, 2011-2013.